Report
Two-compartment tumor metabolism: Autophagy in the tumor microenvironment and oxidative mitochondrial metabolism (OXPHOS) in cancer cells
Downloads and Tools
Volume 11, Issue 13 July 1, 2012
Pages 2545 - 2559
http://dx.doi.org/10.4161/cc.20920
Keywords: AMP kinase (AMPK), DNA damage response, DRAM, GOLPH3, LKB1, autophagy, cancer metabolism, cancer-associated fibroblasts, glycolysis, oxidative mitochondrial metabolism (OXPHOS), tumor stroma
Authors: Ahmed F. Salem, Diana Whitaker-Menezes, Zhao Lin, Ubaldo E. Martinez-Outschoorn, Herbert B. Tanowitz, Mazhar Salim Al-Zoubi, Anthony Howell, Richard G. Pestell, Federica Sotgia and Michael P. Lisanti
View affiliations Hide affiliations
- Ahmed F. Salem
-
The Jefferson Stem Cell Biology and Regenerative Medicine Center; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; Departments of Stem Cell Biology & Regenerative Medicine, and Cancer Biology; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; Department of Molecular Drug Evaluation, Division of Biochemistry; National Organization for Drug Control and Research; Giza, Egypt
- Diana Whitaker-Menezes
-
The Jefferson Stem Cell Biology and Regenerative Medicine Center; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; Departments of Stem Cell Biology & Regenerative Medicine, and Cancer Biology; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA
- Zhao Lin
-
The Jefferson Stem Cell Biology and Regenerative Medicine Center; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; Departments of Stem Cell Biology & Regenerative Medicine, and Cancer Biology; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA
- Ubaldo E. Martinez-Outschoorn
-
The Jefferson Stem Cell Biology and Regenerative Medicine Center; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; Departments of Stem Cell Biology & Regenerative Medicine, and Cancer Biology; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; Department of Medical Oncology; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA
- Herbert B. Tanowitz
-
Departments of Pathology and Medicine; Albert Einstein College of Medicine; Bronx, NY USA
- Mazhar Salim Al-Zoubi
-
The Jefferson Stem Cell Biology and Regenerative Medicine Center; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; Departments of Stem Cell Biology & Regenerative Medicine, and Cancer Biology; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA
- Anthony Howell
-
Manchester Breast Centre & Breakthrough Breast Cancer Research Unit, Paterson Institute for Cancer Research; School of Cancer, Enabling Sciences and Technology, Manchester Academic Health Science Centre; University of Manchester; UK
- Richard G. Pestell
-
The Jefferson Stem Cell Biology and Regenerative Medicine Center; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; Departments of Stem Cell Biology & Regenerative Medicine, and Cancer Biology; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; Department of Medical Oncology; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA
- Federica Sotgia
-
Corresponding author: fsotgia@gmail.com
The Jefferson Stem Cell Biology and Regenerative Medicine Center; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; Departments of Stem Cell Biology & Regenerative Medicine, and Cancer Biology; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; Manchester Breast Centre & Breakthrough Breast Cancer Research Unit, Paterson Institute for Cancer Research; School of Cancer, Enabling Sciences and Technology, Manchester Academic Health Science Centre; University of Manchester; UK
- Michael P. Lisanti
-
Corresponding author: michaelp.lisanti@gmail.com
The Jefferson Stem Cell Biology and Regenerative Medicine Center; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; Departments of Stem Cell Biology & Regenerative Medicine, and Cancer Biology; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; Department of Medical Oncology; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; Manchester Breast Centre & Breakthrough Breast Cancer Research Unit, Paterson Institute for Cancer Research; School of Cancer, Enabling Sciences and Technology, Manchester Academic Health Science Centre; University of Manchester; UK
Abstract:
Previously, we proposed a new paradigm to explain the compartment-specific role of autophagy in tumor metabolism. In this model, autophagy and mitochondrial dysfunction in the tumor stroma promotes cellular catabolism, which results in the production of recycled nutrients. These chemical building blocks and high-energy “fuels” would then drive the anabolic growth of tumors, via autophagy resistance and oxidative mitochondrial metabolism in cancer cells. We have termed this new form of stromal-epithelial metabolic coupling: “two-compartment tumor metabolism.” Here, we stringently tested this energy-transfer hypothesis, by genetically creating (1) constitutively autophagic fibroblasts, with mitochondrial dysfunction or (2) autophagy-resistant cancer cells, with increased mitochondrial function. Autophagic fibroblasts were generated by stably overexpressing key target genes that lead to AMP-kinase activation, such as DRAM and LKB1. Autophagy-resistant cancer cells were derived by overexpressing GOLPH3, which functionally promotes mitochondrial biogenesis. As predicted, DRAM and LKB1 overexpressing fibroblasts were constitutively autophagic and effectively promoted tumor growth. We validated that autophagic fibroblasts showed mitochondrial dysfunction, with increased production of mitochondrial fuels (L-lactate and ketone body accumulation). Conversely, GOLPH3 overexpressing breast cancer cells were autophagy-resistant, and showed signs of increased mitochondrial biogenesis and function, which resulted in increased tumor growth. Thus, autophagy in the tumor stroma and oxidative mitochondrial metabolism (OXPHOS) in cancer cells can both dramatically promote tumor growth, independently of tumor angiogenesis. For the first time, our current studies also link the DNA damage response in the tumor microenvironment with “Warburg-like” cancer metabolism, as DRAM is a DNA damage/repair target gene.
Received: May 24, 2012; Accepted: May 29, 2012
Preview: